Belite Bio (BLTE) Competitors $61.48 -0.82 (-1.32%) Closing price 04/30/2025 04:00 PM EasternExtended Trading$59.96 -1.52 (-2.47%) As of 08:08 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BLTE vs. LNTH, RVMD, BBIO, LEGN, TGTX, TLX, BPMC, SRPT, AXSM, and NUVLShould you be buying Belite Bio stock or one of its competitors? The main competitors of Belite Bio include Lantheus (LNTH), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Legend Biotech (LEGN), TG Therapeutics (TGTX), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Blueprint Medicines (BPMC), Sarepta Therapeutics (SRPT), Axsome Therapeutics (AXSM), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry. Belite Bio vs. Lantheus Revolution Medicines BridgeBio Pharma Legend Biotech TG Therapeutics Telix Pharmaceuticals Limited American Depositary Shares Blueprint Medicines Sarepta Therapeutics Axsome Therapeutics Nuvalent Belite Bio (NASDAQ:BLTE) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation, community ranking and profitability. Do analysts rate BLTE or LNTH? Belite Bio presently has a consensus target price of $96.67, suggesting a potential upside of 57.23%. Lantheus has a consensus target price of $129.43, suggesting a potential upside of 24.05%. Given Belite Bio's higher probable upside, equities research analysts clearly believe Belite Bio is more favorable than Lantheus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Belite Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Lantheus 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in BLTE or LNTH? 0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Comparatively, 1.5% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more volatility & risk, BLTE or LNTH? Belite Bio has a beta of -1.52, suggesting that its share price is 252% less volatile than the S&P 500. Comparatively, Lantheus has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500. Does the MarketBeat Community believe in BLTE or LNTH? Lantheus received 308 more outperform votes than Belite Bio when rated by MarketBeat users. However, 97.14% of users gave Belite Bio an outperform vote while only 66.02% of users gave Lantheus an outperform vote. CompanyUnderperformOutperformBelite BioOutperform Votes3497.14% Underperform Votes12.86%LantheusOutperform Votes34266.02% Underperform Votes17633.98% Does the media favor BLTE or LNTH? In the previous week, Lantheus had 21 more articles in the media than Belite Bio. MarketBeat recorded 23 mentions for Lantheus and 2 mentions for Belite Bio. Lantheus' average media sentiment score of 1.25 beat Belite Bio's score of 1.23 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 16 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is BLTE or LNTH more profitable? Lantheus has a net margin of 28.57% compared to Belite Bio's net margin of 0.00%. Lantheus' return on equity of 44.29% beat Belite Bio's return on equity.Company Net Margins Return on Equity Return on Assets Belite BioN/A -31.94% -30.73% Lantheus 28.57%44.29%23.52% Which has stronger earnings and valuation, BLTE or LNTH? Lantheus has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBelite BioN/AN/A-$31.63M-$1.18-52.10Lantheus$1.53B4.66$326.66M$4.3723.88 SummaryLantheus beats Belite Bio on 13 of the 16 factors compared between the two stocks. Get Belite Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLTE vs. The Competition Export to ExcelMetricBelite BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.98B$6.89B$5.56B$7.82BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-55.397.4422.5118.48Price / SalesN/A242.70395.68103.60Price / CashN/A65.8538.1834.62Price / Book18.746.516.774.25Net Income-$31.63M$143.21M$3.22B$248.23M7 Day Performance3.17%1.98%1.45%0.89%1 Month Performance-5.42%6.89%3.97%3.53%1 Year Performance49.88%-2.52%16.14%5.08% Belite Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLTEBelite Bio2.8216 of 5 stars$61.48-1.3%$96.67+57.2%+51.4%$1.98BN/A-55.3910News CoveragePositive NewsLNTHLantheus3.9711 of 5 stars$100.62-0.7%$129.43+28.6%+56.8%$6.89B$1.53B16.74700Upcoming EarningsPositive NewsRVMDRevolution Medicines3.7636 of 5 stars$36.56-0.5%$66.67+82.3%+8.3%$6.80B$742,000.00-10.18250Upcoming EarningsAnalyst ForecastPositive NewsBBIOBridgeBio Pharma4.5498 of 5 stars$33.51-1.1%$53.00+58.2%+49.7%$6.37B$221.90M-11.76400Earnings ReportAnalyst ForecastOptions VolumeNews CoverageGap UpLEGNLegend Biotech2.6303 of 5 stars$32.24-1.7%$79.00+145.0%-20.1%$5.92B$627.24M-33.941,070Positive NewsTGTXTG Therapeutics3.327 of 5 stars$36.97-3.5%$40.67+10.0%+233.2%$5.81B$329.00M-369.66290Upcoming EarningsNews CoveragePositive NewsGap DownTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$16.21-3.0%$22.00+35.7%N/A$5.48B$783.21M0.00N/AAnalyst RevisionNews CoverageGap DownBPMCBlueprint Medicines2.5598 of 5 stars$84.18-0.6%$124.95+48.4%-2.0%$5.38B$508.82M-77.94640Analyst ForecastPositive NewsSRPTSarepta Therapeutics4.678 of 5 stars$55.23+2.7%$158.70+187.3%-50.7%$5.36B$1.90B44.18840AXSMAxsome Therapeutics4.8386 of 5 stars$103.00-1.4%$169.80+64.9%+52.2%$5.02B$385.69M-17.20380Upcoming EarningsAnalyst ForecastShort Interest ↓Positive NewsNUVLNuvalent1.891 of 5 stars$69.95-2.4%$115.50+65.1%+11.4%$5.01BN/A-20.1640Upcoming EarningsPositive News Related Companies and Tools Related Companies LNTH Alternatives RVMD Alternatives BBIO Alternatives LEGN Alternatives TGTX Alternatives TLX Alternatives BPMC Alternatives SRPT Alternatives AXSM Alternatives NUVL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BLTE) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Belite Bio, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Belite Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
